Search | Clinical Trials Finder

Conditions: Urinary Bladder, Neurogenic
Interventions: Urodynamics Testing; Device
Lead sponsor: Christopher Cooper; Other
Eligibility: 1 Year to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Urinary Tract Infections
Interventions: Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture; Diagnostic Test
Lead sponsor: Pathnostics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Barrington, Illinois

Conditions: Overactive Bladder
Interventions: OnabotulinumtoxinA 100 Units; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Greensboro, North Carolina • Winston-Salem, North Carolina

Conditions: Chronic Spinal Cord Injury, Neurogenic Bladder
Interventions: High Dose, Low dose; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Frequency, Urge Incontinence, Neurogenic Bladder
Interventions: Lidocaine 2% without vessel constrictor; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Urinary Bladder, Neurogenic
Interventions: Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin, Fesoterodine PR, Fesoterodine BIC 2 mg, Fesoterodine BIC 4 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 18
States / cities: Tucson, Arizona • Orange, California • Atlanta, Georgia + 8 more

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Bladder Outlet Obstruction, Multiple Sclerosis, Cauda Equina Syndrome, Enlarged Prostate With Lower Urinary Tract Symptoms, Parkinson Disease, Lower Urinary Tract Symptoms, Detrusor Underactivity, Spinal Cord Injuries
Interventions: Intermittent self-catheterisation; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: West Orange, New Jersey • Philadelphia, Pennsylvania

Conditions: Overactive Bladder Syndrome, Neuropathic Bladder
Interventions: Oxybutynin Transdermal Patch, Oral Oxybutynin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 4 Years to 8 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Urinary Retention, Neurogenic Bladder, Urologic Diseases
Interventions: Connected Urinary Catheter; Device
Lead sponsor: Spinal Singularity; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Downey, California • Inglewood, California • Murrieta, California + 6 more

Conditions: Overactive Bladder
Interventions: Autologous neobladder construct; Biological
Lead sponsor: Tengion; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions: Intra-detrusor injection of Onabotulinumtoxin-A; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spinal Cord Injuries, Neurogenic Lower Urinary Tract Dysfunction, Neurogenic Bladder
Interventions: Not listed
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Neurogenic Bladder Dysfunction Nos, Spinal Cord Injury
Interventions: BOTOX-A, Saline injection; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Urinary Retention, Neurogenic Bladder
Interventions: C2P; Device
Lead sponsor: Spinal Singularity; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Peoria, Arizona • Surprise, Arizona • Downey, California + 5 more

Conditions: Spinal Cord Injuries
Interventions: Variable-dose TTNS Protocol 5 x week, Fixed-dose TTNS Protocol, Variable-dose TTNS Protocol 2 x week; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Houston, Texas

Conditions: Overactive Bladder
Interventions: botulinum toxin Type A (200U), botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U); Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Middlebury, Connecticut

Conditions: Spinal Cord Injuries, Neurogenic Bladder
Interventions: Locomotor Training; Procedure
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 18 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Spinal Cord Injuries
Interventions: Bladder chemodenervation (Botox), Bladder Sham (Saline) Injection Procedure; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Bladder Cancer, Neurogenic Bladder Disorder, Cystectomy
Interventions: Fitbit Sense 2, Smartphone application survey; Device · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions: Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna; Drug
Lead sponsor: Edgar LeClaire, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: Spinal Cord Injury, Spinal Cord Disease
Interventions: Empowerment Program; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Retention, Neurogenic Bladder
Interventions: An intermittent urethral urinary catheter with a tip, tube and drainage eyelets; Device
Lead sponsor: Hollister Incorporated; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Libertyville, Illinois

Search by objective public record fields.

Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use

Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection

Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?

Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

GentleCath™ for Men Intermittent Catheter With FeelClean™ Technology

Oxybutynin for Post-surgical Bladder Pain and Urgency

Connected Catheter- Safety and Effectiveness Study

Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

Patient and Caregiver Perspectives on Intravesical Instillations for Urinary Symptoms

Botox-A Injection to Improve Bladder Function in Early Spinal Cord Injury (#H-20344)

Connected Catheter (C2P) Study for Bladder Management

Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Pediatric Locomotor Training Bladder Study

Early BOTOX After Spinal Cord Injury

Use of Wearables Following Cystectomy- Part II

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

Empowerment Program to Reduce Treatment of Asymptomatic Bacteriuria in Veterans With Spinal Cord Injury

Consumer Evaluation of an Investigational Intermittent Catheter